Paradigm Biopharmaceuticals (ASX:PAR) DeferredTaxAndRevenue: A$0.00 Mil (As of Dec. 2025)


ASX:PAR Paradigm Biopharmaceuticals Ltd ASX:PAR
27 GF Score
Price A$0.18
! 4 Warning Signs
View Full Analysis

What is Paradigm Biopharmaceuticals DeferredTaxAndRevenue?

Paradigm Biopharmaceuticals ASX:PAR 27 DeferredTaxAndRevenue is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:PAR with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Paradigm Biopharmaceuticals's current deferred tax and revenue for the quarter that ended in Dec. 2025 was A$0.00 Mil.

Paradigm Biopharmaceuticals DeferredTaxAndRevenue Related Terms

Paradigm Biopharmaceuticals DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Paradigm Biopharmaceuticals's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paradigm Biopharmaceuticals DeferredTaxAndRevenue Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Paradigm Biopharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:PAR
27GF Score
Paradigm Biopharmaceuticals Ltd ASX:PAR
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of A$0.00 Mil mean?
Paradigm Biopharmaceuticals (ASX:PAR) has a DeferredTaxAndRevenue of A$0.00 Mil as of Dec. 2025. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Paradigm Biopharmaceuticals.
Is Paradigm Biopharmaceuticals' DeferredTaxAndRevenue too high?
Paradigm Biopharmaceuticals' current DeferredTaxAndRevenue is A$0.00 Mil. Overall, Paradigm Biopharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Paradigm Biopharmaceuticals' DeferredTaxAndRevenue compare to VRTX and REGN?
Paradigm Biopharmaceuticals' DeferredTaxAndRevenue of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Paradigm Biopharmaceuticals. Paradigm Biopharmaceuticals's current DeferredTaxAndRevenue is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paradigm Biopharmaceuticals stock overvalued right now?
Paradigm Biopharmaceuticals (ASX:PAR) has a current DeferredTaxAndRevenue of A$0.00 Mil. The current DeferredTaxAndRevenue is A$0.00 Mil. Paradigm Biopharmaceuticals' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Paradigm Biopharmaceuticals (ASX:PAR), the current DeferredTaxAndRevenue is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Paradigm Biopharmaceuticals Business Description

Other Exchanges PBIGF:USAP86:Germany
Address 500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a late-stage clinical development company engaged in the research and development of therapeutic products for human use in Australia. The firm is engaged in developing injectable pentosan polysulfate sodium (iPPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The company has registered the trademarks Zilosul and Rhinosul for the commercialization of iPPS.
27GF Score

Get the complete analysis for ASX:PAR

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.18
Price